Healx deploys its AI in hunt for Friedreich’s ataxia therapiesUK artificial intelligence specialist Healx has begun a partnership with two medical charities that aims to uncover new Share XHealx deploys its AI in hunt for Friedreich’s ataxia therapieshttps://pharmaphorum.com/news/healx-deploys-its-ai-in-hunt-for-friedreichs-ataxia-therapies/
AI drug discovery firm Valence joins Parkinson’s disease pushCanada’s Valence Discovery has joined a University of Montreal-led project to try to find new drugs to treat Share XAI drug discovery firm Valence joins Parkinson’s disease pushhttps://pharmaphorum.com/news/ai-drug-discovery-firm-valence-joins-parkinsons-disease-push/
Biotech trends in COVID era: the pharmaphorum podcastIn episode 26 the pharmaphorum podcast hears from David Solomon, a 30-year life sciences industry veteran who recently Share XBiotech trends in COVID era: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/biotech-trends-pharnext-david-solomon/
Biogen teams up with gene-editing startup Scribe on ALS programmeScribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 Share XBiogen teams up with gene-editing startup Scribe on ALS programmehttps://pharmaphorum.com/news/biogen-teams-up-with-gene-editing-startup-scribe-on-als-programme/
Evotec and Celgene unite to drive forward oncology R&DEvotec and Celgene have joined forces in a long-term strategic drug discovery and development partnership, to identify new Share XEvotec and Celgene unite to drive forward oncology R&Dhttps://pharmaphorum.com/news/evotec-celgene-unite-drive-forward-oncology-rd/
New HQ to be flagship for UK’s dementia researchThe UK is investing more in its ‘Grand Challenge’ to tackle dementia, with a £40 million investment in Share XNew HQ to be flagship for UK’s dementia researchhttps://pharmaphorum.com/news/new-hq-flagship-uks-dementia-research/
